<DOC>
	<DOCNO>NCT00669071</DOCNO>
	<brief_summary>This study evaluate efficacy safety Tri-Luma® Cream ( fluocinolone acetonide 0.01 % , hydroquinone 4 % , tretinoin 0.05 % ) use sequentially series intense pulse light ( IPL ) treatments Subjects diagnose moderate severe melasma 10 week treatment period .</brief_summary>
	<brief_title>Treatment w/ Tri-Luma® Cream &amp; Intense Pulsed Light ( IPL ) v Mild Inactive Control Cream &amp; Intense Pulsed Light ( IPL ) Melasma</brief_title>
	<detailed_description>Same .</detailed_description>
	<mesh_term>Melanosis</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<mesh_term>Hydroquinone</mesh_term>
	<criteria>Subjects diagnose moderate severe melasma side face ( Investigator 's Global Assessment ( IGA ) baseline must 3 4 . ) Subjects diagnosis skin cancer ( Basal Cell Carcinoma ( BCC ) , Squamous Cell Carcinoma ( SCC ) , Melanoma ) area treat Subjects prior facial Intense Pulsed Light ( IPL ) , resurface , deep chemical peel within 6 month date study entry Subject initiate treatment hormone include estrogen , progesterone and/or oral contraceptive within 3 month study entry , intend discontinue hormonal therapy study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>